Form 4: Relmada Therapeutics Director Paul Kelly Acquires and Forfeits Stock Options

Director Paul Kelly acquired and simultaneously forfeited stock options in Relmada Therapeutics on May 24, 2024, related to the company's 2021 Equity Incentive Plan.

Summary

• On May 24, 2024, Paul Kelly, a director of Relmada Therapeutics, acquired options for 43,700 shares under the company's 2021 Equity Incentive Plan.
• These options were part of an 'Additional Award Shares' allocation, stemming from expirations, cancellations, forfeitures, and terminations of other outstanding awards under the plan since December 15, 2023.
• On the same day, Kelly voluntarily forfeited these 43,700 options back to the issuer.
• The forfeited shares are intended to be reallocated to holders of similar awards who are not executive officers or directors of the Issuer.
• Following these transactions, Kelly directly owns 65,672 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document reports a routine transaction of stock options, with a voluntary forfeiture suggesting a focus on equitable distribution within the company.

Positives

• The reallocation of forfeited options to non-executive employees could improve morale and align incentives.
• The forfeiture demonstrates a commitment to equitable distribution of equity awards within the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in Paul Kelly's beneficial ownership of Relmada Therapeutics' securities.

Stakeholder Impact

• The reallocation of forfeited options could positively impact non-executive employees by providing them with additional equity incentives.
• Shareholders may view the forfeiture as a sign of good corporate governance.

Key Dates

Keywords

stock options, Relmada Therapeutics, Form 4, equity incentive plan, beneficial ownership, Paul Kelly, forfeiture, RLMD, director